Adma Biologics Inc

NASDAQ:ADMA  
1.72
+0.10 (+5.86%)
Earnings Announcements

ADMA Biologics Reports Fourth Quarter And Full Year 2020 Financial Results

Published: 03/25/2021 20:22 GMT
Adma Biologics Inc (ADMA) - Adma Biologics Reports Fourth Quarter and Full Year 2020 Financial Results.
Q4 Loss per Share $0.20.
Q4 Revenue $14 Million Versus Refinitiv Ibes Estimate of $12.9 Million.
Q4 Earnings per Share Estimate $-0.16 -- Refinitiv Ibes Data (analyst estimates).
Anticipates Having 10 Or More Plasma Collection Centers in Operation by 2024.
at Dec 31, 2020, Adma Had Cash, Cash Equivalents of $55.9 Million and Accounts Receivable of $13.2 Million.
Revenue is expected to be $16.03 Million
Adjusted EPS is expected to be -$0.16

Next Quarter Revenue Guidance is expected to be $18.13 Million
Next Quarter EPS Guidance is expected to be -$0.14

More details on our Analysts Page.